Company ProfilePremium

AVI Products India Limited

Company Profile Analysis

Ticker: 523896.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
AVI Products India Limited - Company showcase

Year Founded & Workforce

1989

AVI Products India Limited logo

AVI Products India Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

AVI Products India Limited Overview

AVI Products India Limited is a 37-year-old, BSE-listed micro-entity. It spent most of the last decade as an asset-light trader of dental consumables and equipment, selling through its own e-commerce site Dentaldeal.in. Alongside that it ran IFRUIT, a small franchise-led ice-cream and waffle format. Peak revenue was only ₹4.85 crore (FY2024). Operating revenue fell to zero by the June 2026 quarter as the founding Vora family wound the business down ahead of selling control. In February 2026 PPMS Real Estates LLP, a Mumbai real-estate platform with experience in Slum Rehabilitation Authority (SRA) redevelopment, agreed to acquire control. It completed a mandatory open offer at ₹33 per share and now owns 62.83%. Shareholders have authorised a pivot into real estate, healthcare, chemicals and IT, plus ₹100 crore of borrowing capacity. The listed entity is now best characterised as a clean, low-debt listed shell. Its future value depends almost entirely on what the new promoter injects into it, and on what governance safeguards come with that.


The company's own description

The company's filings consistently describe it as trading dental products and equipment. The FY2025 directors' report (36th Annual Report) states that the company is in the trading of dental products and equipment. The FY2024 annual report gives a broader business description: AVI acts across India and globally as an advisor, consultant, planner, trainer, intermediary, broker, publisher, developer, agent, contractor and service provider in the dental, medical, diagnostic and healthcare sectors (Screener.in, citing FY2024 Annual Report p.9).

The company summary on IndiaInfoline, derived from the company's corporate profile, makes these points:

  • AVI began as a trader of chemicals and an e-commerce operator.

  • It moved into dental and healthcare distribution, and into food and beverage franchising under IFRUIT.

  • It began marketing Indian-made endodontic files. It used digital marketing to reach dentists directly and passed on the dealer margin it bypassed.

  • After the change in management, the object clause was amended on 28 May 2026 so the company can undertake real-estate business from FY2027 onwards.

Independent characterisation

AVI historically had two businesses.

Dental e-commerce and trading (Dentaldeal.in). This was a B2B and B2C online catalogue selling third-party and private-label dental consumables and small equipment to dental clinics and practitioners across India. The model was pure trading:

  • Goods were bought from manufacturers and importers and resold online.

  • Revenue was recognised on product sale, and gross margins were roughly 33–39% (FY2022–FY2025, StockAnalysis.com).

  • Value-chain position was downstream distribution and retail. There was no manufacturing, no proprietary technology and no recurring subscription income.

Food & Beverages (IFRUIT). IFRUIT began as company-run ice-cream parlours in Mumbai using imported machinery. It then shifted to a franchise model. Revenue came from three sources:

  • franchise fees,

  • sales of ice-cream machines (stir-fried "roll" ice-cream pans, hard ice-cream, soft-serve and popsicle machines) to franchisees,

  • sales of ingredients and consumables.

The company reported more than 40 outlets, offered five franchise formats, and stated an ambition to reach 200 franchises within two years. That target has not been reported as achieved in any later filing reviewed.

Revenue model mix. No numerical split is disclosed in the sources reviewed. Qualitatively:

  • Product trading (dental) was the dominant line, since the annual reports describe the company as a dental trader.

  • Franchise fees and machine sales (F&B) were a minority.

  • There was no subscription, licensing or service revenue of significance.

Customer types and end-markets. Customers were dental practitioners, dental clinics and hospitals across India, plus IFRUIT franchisees (small entrepreneurs in tier-2 and tier-3 cities). The end-markets were Indian dental consumables and equipment, and Indian QSR/dessert retail. The FY2025 directors' report recorded nil foreign-currency expenditure, so operations were domestic.

Current state (October 2026).

  • Operating revenue was zero in Q1 FY2027 (quarter ended 30 June 2026). Total income of ₹7.80 lakh came entirely from other income.

  • Inventories fell to ₹123.22 lakh at 31 March 2026, and property, plant & equipment fell to ₹14.59 lakh.

  • The 37th AGM approved the sale of company-owned assets to the outgoing promoters and a director.

  • The legacy businesses are therefore being run off.

  • The new object clause covers real-estate development and construction, healthcare services and medical tourism, internet services, and chemical and food manufacturing (Whalesbook summary of the postal ballot outcome, 30 May 2026). No new business revenue has been reported yet.

Strategy

Stated strategy

There is no investor-day or strategy document. Strategic intent has to be inferred from shareholder resolutions and board actions:

  1. Pivot to real estate. The object clause was amended (approved 30 May 2026; IndiaInfoline records the change as dated 28 May 2026) so the company can carry on real-estate business from FY2027. The new CIN carries the real-estate NIC code (68200). The new MD's background is in SRA redevelopment, joint ventures and valuation.

  2. Broad diversification optionality. The objects also cover chemicals and petrochemicals, healthcare and medical tourism, IT consultancy, internet services, food manufacturing and e-commerce (Whalesbook, 30 May 2026).

  3. Balance-sheet capacity. Shareholders approved:

    • borrowing powers of up to ₹100 crore under Section 180(1)(c),

    • creation of charges on assets under Section 180(1)(a),

    • loans, guarantees and investments of up to ₹100 crore under Sections 185 and 186. That is about 19x the FY2026 net worth of ₹5.16 crore.

  4. Related-party ecosystem. Material related-party transactions were approved with 45 entities for FY2027, capped at ₹25 crore per entity. Activities covered include real estate, consultancy and investments. Named counterparties include Paradigm Realty Pvt Ltd and PPMS Real Estates LLP. The theoretical aggregate ceiling is ₹1,125 crore (45 × ₹25 crore).

  5. Legacy run-off. Operating revenue was zero in Q1 FY2027, and assets are being sold to the outgoing promoters and a director (37th AGM approval).

Medium-term financial targets or guidance: none disclosed. Historically, management talked of scaling IFRUIT to 200 franchises within two years; that target is now superseded.

Initiatives in the last 24 months

DateInitiativeDetailStatus
Jan 2026Governance refreshNew independent and non-executive directors, new CS, auditor and secretarial auditor appointmentsSuperseded by the April 2026 reconstitution
Feb–Jun 2026Change of controlAcquisition by PPMS Real Estates LLP plus mandatory open offerCompleted 10 June 2026
Apr 2026Registered office moveVasai to Khar (West), MumbaiEffective 23 April 2026
May 2026Object-clause amendmentReal estate and diversified objectsApproved
May 2026₹100 crore borrowing and loan/investment limitsSections 180, 185, 186Approved; no borrowing drawn as of FY2026 (borrowings ₹0.01 crore)
May 2026Material RPT framework45 entities, ₹25 crore each, FY2027Approved; promoter group abstained
Jun–Sep 2026Legacy asset disposalCars sold to Avinash Vora for ₹5,23,660; broader asset sale to promoters and directorCar sale due by 31 October 2026; broader sale approved 24 September 2026
Aug 2026New MDParthh K. Mehta appointed for 5 yearsApproved at AGM

ESG or sustainability commitments: none disclosed. Cost programmes: none formally announced, although quarterly expenses fell from ₹102.18 lakh (Q1 FY2026) to ₹27.67 lakh (Q1 FY2027).

Products & Services

Pricing, launch years and technical specifications for individual SKUs are not publicly disclosed. The catalogue below is compiled from company descriptions reproduced by Simply Wall St, Investing.com and IndiaInfoline, and from Screener.in's annual-report extracts.

E-commerce & Trading segment (Dentaldeal.in)

Product lineDescription / capabilityTarget customerPricing model
Endo-motorsMotorised handpieces that drive rotary root-canal filesEndodontists, general dentistsUnit sale; price not disclosed
Intra-oral camerasChairside imaging devices for patient communication and recordsDental clinicsUnit sale; not disclosed
LED light-curing machinesUnits that polymerise composite restorationsGeneral dentistsUnit sale; not disclosed
Autoclave productsSteam sterilisers for instrumentsClinics, hospitalsUnit sale; not disclosed
UV chambersUltraviolet storage and disinfection cabinets for instrumentsClinicsUnit sale; not disclosed
Dental X-ray developers & fixersFilm-processing chemicals, a legacy of the "Photochem" heritageClinics using film radiographyConsumable; not disclosed
Composite filling materialsTooth-coloured restorative resinsGeneral dentistsConsumable; not disclosed
Root-canal (endodontic) filesIndian-made files, described by the company as a fast-moving product and promoted via digital marketingEndodontists, general dentistsConsumable; not disclosed
Orthodontic materialsBrackets, wires and accessories (specific items not detailed)OrthodontistsConsumable; not disclosed
Dental chemicals — EtchantAcid etching gel for bondingGeneral dentistsConsumable; not disclosed
Dental chemicals — Root HelpEndodontic chemical (named product; composition not disclosed)EndodontistsConsumable; not disclosed
Dental chemicals — Root CalRoot-canal medicament, likely calcium-hydroxide based (composition not disclosed)EndodontistsConsumable; not disclosed
Dental chemicals — DesensitizerDentine desensitising agentGeneral dentistsConsumable; not disclosed

Flagship offering: Indian-made endodontic files sold direct to practitioners, as highlighted in the company profile.

Food & Beverages segment (IFRUIT)

Product / formatDescriptionTarget customerPricing model
Ice-cream rolls ("rollies")Stir-fried / cold-plate rolled ice-creamConsumers via franchise outletsRetail; not disclosed
Ice-cream candies / kulfisFrozen novelty itemsConsumersRetail; not disclosed
Sorbets and gelatosFrozen dessertsConsumersRetail; not disclosed
JuicesFresh beveragesConsumersRetail; not disclosed
Sundaes and fusionsComposite dessertsConsumersRetail; not disclosed
Frosties, smoothies, milkshakesBlended beveragesConsumersRetail; not disclosed
Belgian wafflesWaffle dessertsConsumersRetail; not disclosed
Single-pan stir-fried ice-cream machineEquipment for rolled ice-creamFranchiseesEquipment sale; not disclosed
Small hard ice-cream machineBatch freezerFranchiseesEquipment sale; not disclosed
Table-top soft-serve machineSoft-serve dispenserFranchiseesEquipment sale; not disclosed
Popsicle / candy machineStick novelty makerFranchiseesEquipment sale; not disclosed
IFRUIT franchise packagesFive franchise models for different budgets; more than 40 outlets openedSmall entrepreneurs, tier-2/3 townsFranchise fee plus equipment; fees not disclosed
Quick Service Restaurant (QSR) chain (planned)Company stated plans to open a QSR chain for fast foodConsumersNo evidence of execution in the filings reviewed

Prospective portfolio (post-pivot)

The amended object clause (approved 30 May 2026) permits:

  • real-estate development and construction,

  • real-estate consultancy,

  • healthcare services and medical tourism,

  • internet services and IT consultancy,

  • chemicals and petrochemicals,

  • food manufacturing,

  • e-commerce.

No products, projects or services under these objects have been announced as of 20 October 2026.

Financial Narrative

All figures are standalone and in ₹ crore unless stated. The primary source is Screener.in (C-MOTS data compiled from BSE annual and quarterly filings), cross-checked against StockAnalysis.com (₹ million), the FY2025 directors' report (IIFL) and FY2026 audited results (ScanX summary of the 30 May 2026 BSE filing). EBITDA is approximated as operating profit before other income, as Screener defines it. Ratios marked "computed" were calculated by the analyst from these figures.

Income statement

Notes: - FY2022 revenue growth is computed against FY2021 revenue of ₹2.38 crore.

  • No diluted EPS distinct from basic is disclosed, and there are no outstanding convertibles in the sources reviewed.

  • FY2025 reconciliation: the directors' report shows profit before tax of ₹718 thousand and profit after tax of ₹537 thousand, against FY2024 figures of ₹3,262 thousand and ₹2,550 thousand. This matches Screener's ₹0.08 crore and ₹0.05 crore.

Margin profile

Revenue CAGR (computed):

  • FY2022 → FY2025: +12.1% a year (₹3.34 crore to ₹4.70 crore).

  • FY2022 → FY2026: −23.1% a year (₹3.34 crore to ₹1.17 crore).

  • Screener reports 5-year compounded sales growth of −13% and 3-year growth of −31%.

Commentary. Between FY2021 and FY2024 the company was a functioning micro-distributor. Revenue grew from ₹2.38 crore to ₹4.85 crore, helped by post-COVID normalisation of dental practice volumes and IFRUIT franchise additions. Gross margins in the 34–39% range are healthy for a distributor and reflect private-label and direct-to-dentist pricing. However, operating expenses consumed almost all of that gross profit, so EBITDA margins never exceeded 8.3%. The business had no operating leverage: fixed costs (staff, marketing, platform) were large relative to a revenue base of ₹3–5 crore.

Inflection points:

  1. FY2024. Depreciation more than doubled, from ₹0.06 crore to ₹0.14 crore, after fixed assets rose to ₹1.44 crore. Capex was about ₹1.00 crore, apparently on vehicles, equipment and outlet assets.

  2. FY2025. Revenue was flat, but the operating margin collapsed to 0.85% as expenses rose to ₹4.66 crore. Other income of ₹0.24 crore, mainly interest on cash, kept the year profitable.

  3. FY2026. The legacy businesses were wound down. Quarterly revenue fell from ₹0.58 crore (June 2025) to ₹0.08 crore (March 2026). Gross profit turned negative because cost of revenue (₹15.77 million) exceeded revenue (₹11.80 million). This is consistent with inventory liquidation or write-downs. The net loss of ₹1.94 crore wiped out about 27% of opening net worth.

Quarterly trajectory (8 quarters plus latest)

Source: Screener.in. The Q1 FY2027 detail (Capital Market, ScanX, 5–6 August 2026) is:

  • income from operations: nil

  • other income: ₹7.80 lakh

  • total expenses: ₹27.67 lakh

  • loss before tax: ₹19.87 lakh

  • tax credit: ₹2.01 lakh

  • net loss: ₹17.86 lakh, against a loss of ₹39.62 lakh in Q1 FY2026

Balance sheet

Additional FY2025 and FY2026 detail from the audited balance sheet (ScanX summary of the 30 May 2026 BSE filing; ₹ lakh):

A key observation on asset quality. At 31 March 2026, current assets were ₹507.12 lakh. Of that:

  • inventory was ₹123.22 lakh,

  • receivables were ₹20.34 lakh,

  • cash was ₹3.37 lakh.

That leaves about ₹360 lakh (≈₹3.6 crore) of "other current assets," roughly 69% of total assets. Their composition is not disclosed in the summaries reviewed; they could be loans and advances, deposits or other receivables. Cash fell by ₹315.63 lakh during FY2026 while operating cash flow was −₹311.25 lakh. This suggests cash was converted into advances or other current assets classified within operating activities. Identifying the nature and counterparties of these ₹3.6 crore of assets is the single most important diligence item for any investor.

Cash flow

In FY2026, the investing inflow of ₹81.93 lakh came largely from sales of property, plant and equipment. The financing outflow of ₹86.31 lakh included repayment of ₹81.00 lakh of short-term borrowings (ScanX summary of the FY2026 audited cash flow).

Commentary. Free cash flow was negative in every year from FY2022 to FY2026, totalling about −₹4.9 crore. The equity raises of FY2022 and FY2024 (financing inflows of ₹2.09 crore and ₹2.48 crore, mostly preferential capital) funded both the operating cash burn and the FY2024 capex. The company has never paid a dividend (Screener shows 0% payout every year since FY2015).

Ratio analysis

Further notes: - Current ratio (computed): 7.3x at 31 March 2025 and 82.5x at 31 March 2026. Earlier years are not disclosed in the sources reviewed.

  • Net debt / EBITDA is not meaningful: the company held net cash in FY2025 and FY2026 and EBITDA was negative in FY2026.

  • ROIC is not separately disclosed; ROCE is the closest proxy.

  • Screener reports last-year ROE of −23.3%, presumably on a different denominator. MarketInOut reports trailing ROE of −28.71% and ROIC of −44.63%.

Commentary.

Inventory days: These averaged 240–285 days, which is very high even for dental consumables and points to slow-moving stock.

Returns: Combined with thin operating margins, the long inventory cycle kept ROCE in single digits even in the best years.

Leverage: This has never been a concern. The ₹0.82 crore of FY2025 short-term borrowings was repaid in FY2026.

Valuation basis: The working-capital-days figure of 1,553 for FY2026 is an artefact of collapsing revenue against a balance sheet still holding ₹5 crore of current assets. Analytically, the entity is now valued on its net assets plus control/option value, not on earnings.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentWhat it containsProducts / services

E-commerce & Trading

Dental and healthcare products sold through Dentaldeal.in and direct trading

Endo-motors, intra-oral cameras, LED curing lights, autoclaves, UV chambers, X-ray developers and fixers, composites, endodontic files, orthodontic materials, dental chemicals

Food & Beverages

IFRUIT franchise brand

Ice-cream rolls, kulfis and candies, sorbets, gelato, juices, sundaes, shakes and smoothies, Belgian waffles; ice-cream machines sold to franchisees

Results by Segment and Segment Margins & Growth (%)

MetricFY2024FY2025FY2026

Total revenue from operations (INR Cr)

4.854.701.17

YoY growth (%)

34.3-3.1-75.1

Operating profit before other income (INR Cr)

0.260.04-1.48

Operating margin (%)

5.360.85-126.50

Profit before tax (INR Cr)

0.320.08-1.92

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

3.343.614.854.701.17

Revenue growth YoY (%)

40.38.134.3-3.1-75.1

Gross profit (INR Cr; StockAnalysis)

1.261.411.641.56-0.40

Total expenses excl. D&A and interest (INR Cr)

3.123.314.594.662.65

EBITDA / operating profit (INR Cr)

0.220.300.260.04-1.48

Other income (INR Cr)

0.030.080.210.24-0.30

Interest (INR Cr)

0.050.040.010.050.05

Depreciation (INR Cr)

0.040.060.140.150.09

Operating income, StockAnalysis basis (INR Cr)

0.180.230.21-0.09-2.06

Profit before tax (INR Cr)

0.160.280.320.08-1.92

Tax rate (%)

25.0025.0021.8825.001.04

Net income (INR Cr)

0.120.210.260.05-1.94

EPS basic, Screener (INR)

0.460.810.790.15-5.87

EPS diluted (INR)

0.460.810.790.15-5.87

Dividend per share (INR)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%; StockAnalysis)

37.739.133.833.0-33.6

EBITDA / operating margin (%)

6.598.315.360.85-126.50

Pre-tax margin (%; computed)

4.797.766.601.70-164.10

Net margin (%; computed)

3.595.825.361.06-165.81

Income Statement and Per-Share Data

MetricJun-2024Sep-2024Dec-2024Mar-2025Jun-2025Sep-2025Dec-2025Mar-2026Jun-2026

Sales (INR Cr)

1.060.891.131.630.580.190.330.080.00

Expenses (INR Cr)

1.010.831.201.620.960.720.790.700.28

Operating profit (INR Cr)

0.050.06-0.070.01-0.38-0.53-0.46-0.62-0.28

Other income (INR Cr)

0.050.010.110.080.040.020.060.090.08

Profit before tax (INR Cr)

0.050.02-0.030.03-0.40-0.55-0.44-0.55-0.20

Net profit (INR Cr)

0.040.01-0.030.02-0.40-0.55-0.44-0.57-0.18

EPS (INR)

0.120.03-0.090.06-1.21-1.66-1.33-1.72-0.54

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Equity share capital (INR Cr)

2.582.583.313.313.31

Reserves / other equity (INR Cr)

1.761.963.743.791.85

Total equity / net worth (INR Cr)

4.344.547.057.105.16

Borrowings, total (INR Cr)

0.020.010.260.820.01

Other liabilities (INR Cr)

0.430.170.800.080.06

Total assets (INR Cr)

4.794.728.118.005.23

Net fixed assets (INR Cr)

0.450.581.441.360.15

Other assets incl. current (INR Cr)

4.344.146.676.645.08

Goodwill & intangibles (INR Cr)

00000

Balance Sheet (FY2025–FY2026)

Line item (INR Lakh)FY2025FY2026

Total assets

799.48523.51

Non-current assets

143.0916.39

Property, plant & equipment

not separately disclosed in summary

14.59

Current assets

656.39507.12

Inventories

not separately disclosed in summary

123.22

Trade receivables

not separately disclosed in summary

20.34

Cash & cash equivalents

319.003.37

Total current liabilities

89.876.15

Equity share capital

330.68330.68

Other equity

378.93184.67

Liquidity & Coverage Ratios

MetricFY2025FY2026

Cash & equivalents (INR Cr)

3.190.03

Total debt (INR Cr; short-term)

0.820.01

Long-term debt (INR Cr)

00

Net debt (INR Cr; negative = net cash)

-2.37-0.02

Working capital (INR Cr)

5.675.01

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Cr)

0.10-0.620.31-0.77-3.11

Investing cash flow (INR Cr)

-0.09-1.51-0.900.140.82

Financing cash flow (INR Cr)

2.09-0.062.480.50-0.86

Net cash flow (INR Cr)

2.10-2.181.90-0.14-3.16

Net capex (INR Cr; computed as OCF minus FCF; negative = net disposals)

0.120.201.000.10-0.61

Free cash flow (INR Cr; Screener)

-0.02-0.82-0.69-0.87-2.50

Dividends paid (INR Cr)

00000

Share buybacks (INR Cr)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROE on average equity (%; computed)

4.14.74.50.7-31.6

ROA on average assets (%; computed)

3.24.44.10.6-29.3

ROCE (%; Screener)

6.507.185.561.97-20.63

Debt / equity (x; computed)

0.0050.0020.0370.1150.002

Interest coverage, EBIT / interest (x; computed)

4.28.033.02.6-37.4

Asset turnover, sales / average assets (x; computed)

0.900.760.760.580.18

Debtor days (Screener)

44.8142.4760.2176.8862.39

Inventory days (Screener)

276.41282.96251.80241.37284.15

Payable days (Screener)

26.5813.3971.615.899.24

Cash conversion cycle (days; Screener)

294.64312.03240.40312.37337.30

Working capital days (Screener)

177.04250.75165.57191.821,553.59

Revenue by Region and Revenue by Region (%)

RegionFY2024FY2025FY2026

India revenue (INR Cr)

4.854.701.17

Outside India revenue (INR Cr)

000

India share of total (%)

100100100

Capital Markets

Metric1-year3-year CAGR5-year CAGR10-year CAGR

Share price return (%; Screener.in, October 2026)

7818913

Share price return (%; IIFL, 10 August 2026)

66.9918.363.84—

Price Point Details

Price pointDatePrice (INR)Source

Close

26 Dec 2024

24.45

Business Standard

Close

7 May 2025

23.89

Simply Wall St

Close

11 Jul 2025

20.25

IIFL

Close

8 Aug 2025

29.89

Trendlyne

Close

4 May 2026

45.28

Value Research

Close

13 Jul 2026

49.91

Business Today

Close

10 Aug 2026

52.40

IIFL

Close

19 Oct 2026

55.00

Screener.in

Open offer price

Feb–May 2026

33.00

SAST filings

Valuation Multiples

MultipleAVI ProductsComment

P/B

3.53x

Book value per share ₹15.6

EV/Sales (TTM)

~30x

Enterprise value ≈ ₹18.2 crore against TTM sales of ₹0.60 crore. MarketInOut shows 28.95x.

Peer reference: Vasa Denticity P/E

64.36x

As of 1 December 2025 (Kotak Securities)

Peer reference: Vasa Denticity P/B

6.08x

As of 1 December 2025 (Kotak Securities)

Balance Sheet — Dividend per share

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

00000

Dividend payout (%)

00000

Buyback (INR Cr)

00000

Paid-up equity capital (INR Cr)

2.582.583.313.313.31

Margin Analysis (%) (Mar-2017–Sep-2026)

MetricMar-2017Mar-2020Mar-2023Mar-2025Sep-2026

Number of shareholders

13,95413,82513,99814,10813,785

Promoter holding (%)

24.9024.9023.9123.6862.83

Analyst Conclusions

Management guidance and consensus

There is no quantitative guidance and no consensus. The only forward-looking statements are the object-clause change to real estate effective FY2027 and the related-party and borrowing frameworks approved in May 2026.

Bull case

  1. A clean shell with a motivated, domain-expert promoter. PPMS paid to acquire control, did not seek a delisting, and installed an MD with more than 18 years of SRA and joint-venture experience. A modest redevelopment project or consultancy mandate routed into AVI could generate revenue many times the legacy peak of ₹4.85 crore.

  2. Balance-sheet optionality. Debt is near zero and ₹100 crore of borrowing and investment headroom is approved. Combined with residual current assets of about ₹5 crore (if realisable), the listed company can absorb projects quickly.

  3. The cost base has been reset. Quarterly expenses fell from ₹102 lakh to ₹28 lakh year on year (Q1 FY2027), so the cash burn of the legacy business has largely stopped. Any new revenue would flow more directly to profit.

Bear case

  1. There is no business today. Operating revenue is zero and cash was ₹3.37 lakh. The ₹18 crore market capitalisation (3.53x book) prices in a successful pivot that has not been evidenced by a single announced project.

  2. Related-party and governance risk dominates. The approved related-party ceilings total up to ₹1,125 crore across 45 promoter-linked entities. Assets are being sold to outgoing insiders, minority voter participation is about 0.5%, and the board is controller-dominated with CMD duality. Minority shareholders bear asymmetric risk.

  3. Dilution is likely. Any real-estate entry will need equity well above ₹5 crore of net worth, most plausibly through preferential issues to the promoter at prices the minority does not control. Combined with surveillance-category status and thin liquidity, this exposes minorities to sharp drawdowns.

Key catalysts and monitorables (next 12 months)

  1. Q2 FY2027 results, due after the trading window that closed on 1 October 2026. Watch for:

    • any operating revenue,

    • the composition of the ₹3.6 crore of other current assets,

    • the cash position.

  2. Related-party transactions under the 45-entity framework. Watch quarterly Regulation 23 disclosures: counterparties, pricing, valuations.

  3. Fund-raising. Watch for preferential issues or warrants to the promoter, and for use of the ₹100 crore borrowing limit.

  4. First real-estate mandate or project. Watch for RERA registrations, joint development agreements, SRA approvals and consultancy contracts.

  5. Completion and pricing of the asset sale to the outgoing promoters and director approved at the 37th AGM.

  6. Name change. A rebranding away from "AVI Products" would signal commitment to the pivot.

  7. Auditor clarity. Watch for confirmation of the statutory auditor's identity and any qualified opinions.

  8. Surveillance status. Watch for GSM/ASM inclusion and exclusion and for any exchange queries on price movements.

Analyst verdict

AVI Products India Limited no longer exists as an operating business in any economically meaningful sense. For three decades it was a family-run micro-trader. It did eventually build a direct-to-dentist e-commerce niche and a small ice-cream franchise, but it never achieved the scale to earn returns above its cost of capital. Peak revenue was ₹4.85 crore, ROCE peaked at 7%, inventory sat on the shelf for more than 240 days, and free cash flow was negative every year from FY2022 to FY2026. The founding family exited at ₹33 per share in April 2026. Before that, the businesses were run down to zero operating revenue, and the remaining assets are now being sold to the departing insiders.

What investors now own is a listed corporate vehicle controlled by PPMS Real Estates LLP. It has a clean debt profile, a ₹100 crore borrowing mandate, a broad object clause and a related-party framework that allows extensive dealings with promoter entities. The promoter's real-estate credentials are relevant and the vehicle carries genuine option value. But the current valuation of ₹55 per share, 3.5x book and about 30x trailing sales, already capitalises a great deal of that option. This is despite no project, contract or capital plan having been disclosed. Cash at FY2026 was effectively nil, and nearly 70% of assets sit in an undisclosed "other current assets" bucket.

For institutional investors, AVI is uninvestable on fundamentals in its present state. It should be treated as a special situation with binary outcomes:

  • substantial value creation, if the promoter injects profitable real-estate activity on fair terms,

  • or material minority value leakage, if related-party, dilution and governance risks materialise.

We would require three things before taking any constructive view:

  1. full disclosure of the ₹3.6 crore of other current assets,

  2. an announced, arm's-length first project with independent valuation,

  3. clarity on capital-raising terms.

Until then, the appropriate stance is avoid / monitor.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleAppointed / tenureBackground

Parthh Kaushik Mehta

Chairman & Managing Director

Executive Director & Chairman from 23 Apr 2026; MD for 5 years from 5 Aug 2026 (approved at 37th AGM)

More than 18 years in real-estate strategy, valuation and business development. Former CEO of a Mumbai-based real-estate firm. Experienced in Slum Rehabilitation Authority projects and joint ventures. Alumnus of S.P. Jain Centre of Management. Partner in PPMS Real Estates LLP.

Ameya Vivek Tandulkar

Executive Director

23 Apr 2026 to 22 Apr 2031

Business partner of Parthh Mehta in PPMS Real Estates LLP; partner or director in related entities

Bankim Pranjivan Mehta

Non-Executive Director

23 Apr 2026 to 22 Apr 2031

—

Malvika Jagani

Independent Director

23 Apr 2026 to 22 Apr 2031

—

Dayashankar Patel

Independent Director

23 Apr 2026 to 22 Apr 2031

—

Aditya Soni

Independent Director

23 Apr 2026 to 22 Apr 2031

—

Avinash Dhirajlal Vora (DIN 02454059)

Executive Non-Independent Director

Founder. Chairman & MD for about 36 years until he stepped down as MD on 5 Aug 2026. Redesignated for a 5-year term.

Founder of the company; father of director Vikaram Vora

Vikaram Vora (DIN 02454043, per FY2026 AGM notice listing)

Director

Long-tenured; current status after the April 2026 resignations is unconfirmed

Son of Avinash Vora

Manas Ranjan Palo (DIN 01933994)

Independent Director

Appointed 16 Jan 2026 for a term to 15 Jan 2031; current status unconfirmed

—

Saroj Kumar Choudhury (DIN 11143083)

Non-Executive Non-Independent Director

Appointed 16 Jan 2026; current status unconfirmed. Sold shares to PPMS under the SSPC.

—

Chief Financial Officer

—

New CFO appointed 23 Apr 2026; name not available in sources reviewed

—

Company Secretary & Compliance Officer

—

Shanu Jain (ACS A42408) appointed 16 Jan 2026. A new CS was reported appointed on 23 Apr 2026; the name is not available in sources reviewed.

—

“—” = not publicly disclosed.

Executive Leadership Team

ExecutiveFY2020FY2021FY2022FY2023FY2024

Avinash D. Vora, CMD — total compensation (INR Mn)

11121.8

Shareholding Trend

Holder categoryDec-2024Mar-2025Jun-2025Sep-2025Dec-2025Mar-2026Jun-2026Sep-2026

Promoters (%)

23.6823.6823.6823.6823.6823.6862.8362.83

Public (%)

76.3276.3276.3276.3376.3176.3137.1637.17

Number of shareholders

14,08914,10814,08914,00513,92813,86113,82113,785

Major Shareholders

HolderShares%Notes

PPMS Real Estates LLP (promoter)

20,77,683

62.83

Built up as follows: 8,19,868 in market purchases (Feb 2026), 7,83,091 under the SPA, 4,69,710 under the SSPC, and 5,014 through the open offer

Institutional investors (MF/FII/insurance)

—

~0

No institutional holdings reported in the sources reviewed

“—” = not publicly disclosed.

Competitive Landscape

Key Competitors

CompetitorTypeScale indicatorRelative positioning vs AVI

Vasa Denticity Ltd (Dentalkart.com)

NSE-listed dental e-commerce leader

FY2025 sales ₹249.37 crore, net profit ₹16.97 crore, OPM 9.19% (Capital Market, May 2025)

Over 50x AVI's peak revenue; national logistics, private labels, about 335,000 monthly active users (H1 FY2025)

Pinkblue.in

Private dental e-commerce platform

—

Larger online catalogue and VC-backed

Dentganga

Private dental e-commerce platform

—

Direct online competitor

Dental Mantra / Oralkart and similar online sellers

Private online dental retailers

—

Fragmented long tail

Dentsply Sirona (India operations)

Global manufacturer with direct and distributor sales

—

Brand owner; AVI sells adjacent product categories

3M / Solventum Oral Care (India)

Global manufacturer

—

Premium consumables brand

Prevest DenPro Ltd

NSE-listed Indian dental-materials manufacturer

—

Manufacturer of consumables (composites, endodontic materials) that competes with traded SKUs

Local dental dealers (offline)

Fragmented regional distributors

Not quantifiable

Relationship-based; AVI's digital model sought to bypass them

Key Competitors — Natural Ice Cream

CompetitorTypePositioning vs IFRUIT

Natural Ice Cream (Kamath Ourfoods)

Private premium parlour chain

Far larger brand and network

Baskin-Robbins (Graviss Foods, India master franchisee)

Franchise chain

National franchise network

Havmor (Lotte)

Multinational-owned ice-cream brand and parlours

Mass-market scale

Amul

Cooperative mass-market ice cream

Price leader

Kwality Wall's (Hindustan Unilever / successor)

FMCG ice cream

Distribution scale

Belgian Waffle Co.

Franchise dessert QSR

Direct overlap on waffles

Rolled ice-cream kiosks (unbranded)

Local operators

Direct overlap on rolled ice-cream

Peer Comparison FY2026

MetricAVI Products (FY2025)AVI Products (FY2026)Vasa Denticity (FY2025)

Revenue (INR Cr)

4.701.17249.37

Revenue growth YoY (%)

-3.1-75.146.9

Operating margin (%)

0.85-126.509.19

Net profit (INR Cr)

0.05-1.9416.97

R&D intensity (%)

00—

“—” = not publicly disclosed.

Company Snapshot

$0.1M

Revenue

1989

Founded

Some aggregators list Thane, India

Headquarters

SWOT Analysis

Strengths

  • Debt-free balance sheet. Borrowings were ₹0.01 crore at 31 March 2026 after ₹81 lakh of short-term debt was repaid in FY2026 (FY2026 audited cash flow).
  • Large authorised financial flexibility. Shareholders approved ₹100 crore of borrowing, charge-creation and Section 185/186 limits (postal ballot, 30 May 2026), with about 99.998% of votes cast in favour.
  • Committed controlling shareholder. PPMS spent about ₹2.84 crore of committed open-offer consideration plus SPA, SSPC and market purchases to reach 62.83% (post-offer advertisement, 10 June 2026).
  • Real-estate domain expertise at the top. The new MD brings more than 18 years in real-estate strategy, valuation, SRA projects and joint ventures (board resolution, 5 August 2026).
  • Clean listing with a broad retail base. There are 13,785 shareholders (September 2026). The listing has been continuous since the early 1990s, and the acquirer has stated it does not intend to delist (IndiaIPO, February 2026).
  • Historically healthy gross margins in the legacy trade. Gross margin was 33–39% in FY2022–FY2025 (StockAnalysis), showing the direct-to-dentist model had pricing power even without scale.

Weaknesses

  • Zero operating revenue. Q1 FY2027 income from operations was nil (results, 5 August 2026).
  • Severe FY2026 losses. The net loss of ₹1.94 crore cut net worth from ₹7.10 crore to ₹5.16 crore, a 27% erosion (Screener.in; FY2026 results).
  • Cash nearly exhausted. Cash was ₹3.37 lakh at 31 March 2026, against ₹319 lakh a year earlier (FY2026 audited balance sheet).
  • Opaque asset base. About ₹3.6 crore (69% of total assets) sits in other current assets whose composition is undisclosed (derived from the FY2026 balance sheet).
  • Persistently weak returns even at peak. ROCE did not exceed 7.18% between FY2022 and FY2025, and inventory days were 240–285 (Screener.in).
  • Thin disclosure and governance churn. There were two Company Secretary changes in six months (October 2025 to April 2026), mass board resignations on 23 April 2026, and an auditor-identity discrepancy (FRN 104019W reappointed in January 2026 versus SARA & Associates signing the FY2026 accounts).

Opportunities

  • Asset injection or reverse-merger-style value creation. The 45-entity related-party framework at ₹25 crore each lets the promoter route real-estate projects, consultancy income or investments into the listed company (postal ballot, 30 May 2026).
  • Mumbai redevelopment cycle. SRA and society-redevelopment demand matches the promoter's stated expertise (board profile, 5 August 2026).
  • Diversified object clause. Healthcare, medical tourism, IT, chemicals and food manufacturing allow pivots beyond real estate (Whalesbook, 30 May 2026).
  • Leverage capacity. A ₹100 crore borrowing limit on a near-zero-debt base could fund a first project if lenders accept the promoter's credit.
  • Re-rating potential. The stock has risen 78% over one year to ₹55 (Screener.in) on pivot expectations. Visible project announcements could sustain that.
  • Monetisation of residual legacy assets. The sale of inventory (₹123 lakh) and residual assets to the outgoing promoters (AGM, 24 September 2026) could recycle working capital into cash.

Threats

  • Related-party value leakage. Approved related-party limits of up to ₹1,125 crore in aggregate are about 218x FY2026 net worth. This creates a risk of transactions that are not on genuinely arm's-length terms, with minority holders having little practical influence: only 66 of 13,915 shareholders voted in May 2026.
  • Execution risk in a capital-intensive sector. Real estate needs equity far above ₹5 crore of net worth, so dilution through preferential issues is likely.
  • Regulatory scrutiny. The stock has been under GSM/ASM surveillance (August 2025). Sharp price moves around shell pivots attract SEBI and BSE attention.
  • Insider-trading optics. A director appointed on 16 January 2026 acquired 11.04% on 19 January and then sold to the acquirer (SSPC), which could invite regulatory review.
  • Going-concern pressure. Absent new revenue or funding, operating costs (about ₹28 lakh per quarter) exceed the ₹3.37 lakh cash balance. Liquidity depends on the ₹3.6 crore of other current assets and inventory realisation.
  • Liquidity and valuation risk for minorities. Daily volumes are tiny (for example, 70 shares on one day in September 2026; MarketInOut). P/B is 3.53x and EV/revenue about 29x for a company with no operating business, which leaves the share price vulnerable to sharp de-rating if the pivot stalls.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
30 May 2025Board approves Q4 and FY2025 results. Q4 net profit is ₹0.02 crore, down 80% YoY. FY2025 profit after tax is ₹5.37 lakh.Profitability near zero
Aug 2025Stock placed under BSE GSM and ASM surveillance frameworks (as observed 8–14 August 2025)Speculative price action; trading restrictions
14 Aug 2025Q1 FY2026 results: net loss of ₹0.40 crore on sales of ₹0.58 croreStart of decline phase
Aug 202536th AGM convened for 30 September 2025Routine
30 Sep 202536th AGM heldRoutine
28 Oct 2025Company Secretary resignsEarly governance churn
14 Nov 2025Q2 FY2026 results: net loss of ₹0.55 crore on sales of ₹0.19 croreAccelerating run-down
12 Jan 2026Board meeting called to appoint independent directorsPre-transaction governance housekeeping
16 Jan 2026Palo (ID) and Choudhury (NE-NID) appointed; CS Shanu Jain appointed; auditors reappointed; VKMG appointed secretarial auditorBoard refresh
19 Jan 2026Saroj Kumar Choudhury discloses acquisition of 11.04%New director takes a large stake days after appointment, then sells to PPMS in the SSPC
29 Jan 2026Insider-trading disclosure of a share sale by a Joshi family memberInsider selling
3 Feb 2026Jayant Himatlal Joshi sells his entire 2.30% stakeInsider and associate exit
6 Feb 2026Viraaj Pradeep Joshi sells 72,000 sharesInsider and associate exit
Feb 2026Q3 FY2026: net loss of ₹44.25 lakh; revenue down 70.58% to ₹33.22 lakhContinued run-down
11–13 Feb 2026PPMS Real Estates LLP acquires 24.79%Acquirer toehold
14 Feb 2026SPA and SSPC signed; Public Announcement of open offer at ₹33 for 26%Change-of-control trigger
23 Feb 2026Detailed Public Statement publishedOffer formalised
10 Apr 2026Vora family sells 23.68% (SPA); PPMS reaches 59.51%Founder exit
14–15 Apr 2026Individual Regulation 29(2) disclosures by Avinash, Daksha and Parth Vora and another promoter-group memberComplete promoter exit
16 Apr 2026Company confirms it is not a "Large Corporate" for FY2026 debt-raising normsRoutine
22 Apr 2026Further 3.17% acquired by PPMS (Balaji Forex tranche); holding to 62.68%Consolidation
23 Apr 2026Six new directors appointed; resignations of directors, CFO and CS; registered office moved to MumbaiNew management installed
28 Apr 2026Outcome of EGM and scrutiniser's report filed with BSEShareholder process
29 Apr 2026Postal ballot opens on 13 resolutionsPivot approvals sought
2 May 2026Letter of Offer issued; independent directors' committee recommends the offer price as fair (per ScanX headline)Offer process
13–26 May 2026Open offer tendering periodMinimal uptake (5,714 tendered)
28 May 2026Object clause amended to real estate (IndiaInfoline)Strategic pivot
30 May 2026FY2026 audited results: loss of ₹1.94 crore; total assets down to ₹523.51 lakh; cash ₹3.37 lakh; no dividend. Postal ballot passes all 13 resolutions with about 99.998% in favour among votes cast (66 of 13,915 shareholders voted).Pivot approved; legacy losses crystallised
5 Jun 2026Open offer consideration paidOffer completion
10 Jun 2026Post-offer advertisement; PPMS at 62.83%Control finalised
30 Jun 2026Invoice raised for sale of cars to Avinash Vora (₹5.24 lakh)Related-party asset sale
5 Aug 2026Q1 FY2027: zero operating revenue, net loss of ₹17.86 lakh. Parthh Mehta appointed MD; Avinash Vora redesignated.Legacy business at zero
Aug 2026Stock hits 5% upper circuits, reaching ₹52.40 by 10 August 2026 (IIFL)Speculative re-rating on pivot
24 Aug 2026Board meeting fixes AGM date; book closure 18–24 September 2026Routine
27–31 Aug 2026FY2026 Annual Report filed under Regulation 34(1)Disclosure
24 Sep 202637th AGM approves financials, auditors, redesignations, and the sale of assets to promoters and directorLegacy exit authorised
25 Sep 2026Trading window closed from 1 October 2026 until 48 hours after Q2 FY2027 resultsQ2 FY2027 results pending
9 Oct 2026Regulation 74(5) compliance certificate for the September 2026 quarterRoutine

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue from operations fell from INR 33.4 Mn in FY2022 to INR 11.7 Mn in FY2026.
AVI Products India Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue from operations33.436.148.54711.7
Gross profit12.614.116.415.6-4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. BSE Limited corporate filings for scrip 523896: annual reports FY2021–FY2026; quarterly results · SAST disclosures; postal ballot and AGM outcomes; investor-call intimations of 15 February 2023 and 13 June 2024.
  2. Screener.in, AVI Products India Ltd (standalone P&L, balance sheet, cash flow, ratios, shareholding and announcements; data by C-MOTS), accessed 20 October 2026.
  3. StockAnalysis.com income statement, BOM:523896 (FY2022–FY2026).
  4. ScanX (Dhan) summaries of BSE filings dated 16 January, 16 February, 15 April, 12 May, 30 May, 10 June and 5–6 August 2026.
  5. Whalesbook corporate-news summaries, February–May 2026.
  6. IndiaIPO open-offer summary, 16 February 2026.
  7. Capital Market / Business Standard / JM Financial results summaries (2025–2026).
  8. IndiaInfoline company summary and FY2025 directors' report extract.
  9. Simply Wall St (management, compensation, company description).
  10. MarketInOut, Business Today, Value Research, Bajaj Broking, Kotak Neo, Trendlyne and FinancialFilings.com (price, ISIN and market-data points).
  11. Business Standard / Capital Market (Vasa Denticity FY2025 results) and Kotak Securities (Vasa Denticity valuation) for peer benchmarking.

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.